A cell line, designated NOCC, was established from the ascites of a patient with clear cell adenocarcinoma of the ovary. The cell line has been grown without interruption and continuously propagated by serial passaging (more than 76 times) over 7 years. The cells are spherical to polygonal-shaped, display neoplastic, and pleomorphic features, and grow in a jigsaw puzzle-like pattern while forming monolayers without contact inhibition. The cells proliferate rapidly, but are easily floated as a cell sheet. The population doubling time is about 29 h. The number of chromosomes ranges from 60 to 83. The modal number of chromosomes is 70–74 at the 30th passage. NOCC cells secreted 750.5 ng/ml of VEGF over 3 days of culture. Hypoxia inducible factor-1α (HIF-1α) is a primary regulator of VEGF under hypoxic conditions. NOCC cells were not sensitive to the anticancer drugs BEV, DOX, GEM, ETP, CDDP, or TXT. The graft of NOCC cells to a scid mouse displayed similar histological aspects to the original tumor. Both the NOCC cells and the graft of the NOCC cells gave a positive PAS reaction.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Nozawa S, Tsukazaki K, Sakoyori M, et al. Establishment of a human clear cell carcinoma cell line (RMG-1) and its single cell cloning. Hum Cell. 1988;1:426–35.
Wong WSF, Wong YF, Ng YT, Huang PD, Chew EC, Ho TH. Establishment and characterization of a new human cell line. Gynecol Oncol. 1990;38:37–45.
Nozawa S, Yajima M, Sasaki H, et al. A new 125-like antigen (CA602) recognized by two monoclonal antibodies against a newly established ovarian clear cell carcinoma cell line (RMG-II). Jpn J Cancer. 1991;82:854–61.
Yamada K, Tachibana T, Hashimoto H, et al. Establishment and characterization of cell lines derived from serous adenocarcinoma (JHOS-2) and clear cell carcinoma (JHOC-5, JHOC-6) of human ovary. Hum Cell. 1999;12:131–8.
Aoki D, Suzuki N, Susumu N, et al. Establishment and characterization of the RMG-V cell line from human ovarian clear cell carcinoma. Hum Cell. 2005;18:143–6.
Saga Y, Suzuki M, Machida S. Establishment of a new cell line (TAYA) of clear cell adenocarcinoma of the ovary and its radiosensitivity. Oncology. 2002;62:180–4.
Ishiwata I, Ishiwata C, Soma M, et al. Establishment of HUOCA-II, a human ovarian clear cell adenocarcinoma cell line, and its angiogenic activity. J Natl Cancer Res. 1987;78:667–73.
Itomachi H, Kato M, Nishimura M. Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene. Hum Cell. 2013;26:121–7.
Scully RE. World Health Organization classification and nomenclature of ovarian cancer. Natl Cancer Inst Monogr. 1975;42:5–7.
Aure JC, Hoeg K, Kolstad P. Mesonephroid tumors of the ovary. Clinical and histopathologic studies. Obstet Gynecol. 1971;37:860–7.
Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88:2584–9.
Takano M, Kikuchi Y, Yaegashi N, et al. Clear cell carcinoma of the ovary: a retrospective multicenter experience of 254 patients with complete surgical staging. Br J Cancer. 2006;94:1369–74.
Itomachi H, Kigawa J, Sugiyama T, et al. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol. 2002;100:281–7.
Enomoto T, Kuragaki C, Yamasaki M, et al. Is clear cell carcinoma and mucous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? Proc Am Soc Clin Oncol. 2003;22:447.
Tsuchiya A, Sakamoto M, Yasuda J, et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1β as a molecular marker and possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol. 2003;163:2503–12.
Tsukagoshi S, Saga Y, Suzuki N, et al. Thymidine phosphorylase-mediated angiogenesis regulated by thymidine phosphorylase inhibitor in human ovarian cancer cells in vivo. Int J Oncol. 2003;22:961–7.
Semenza GL, Jiang BH, Leung SW, et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem. 1996;271(51):32529–37.
Wenger RH, Kvietikova I, Rolfs A, et al. Hypoxia-inducible factor-1 alpha is regulated at the post-mRNA level. Kidney Int. 1997;51(2):560–3.
Arjamaa O, Nikinmaa M. Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. Exp Eye Res. 2006;83(3):473–83.
Baby SM, Roy A, Mokashi AM, et al. Effects of hypoxia and intracellular iron chelation on hypoxia-inducible factor-1 alpha in the rat carotid body and glomus cells. Histochem Cell Biol. 2003;120(5):343–52.
Sang N, Fang J, Srinivas V, et al. Carboxyl-terminal transactivation activity of hypoxia-inducible factor 1 alpha is governed by a von Hoppel–Lindau protein-independent, hydroxylation-regulated association with p300/CBP. Mol Cell Biol. 2002;22(9):2984–92.
Uesu K, Ishikawa H. Analysis of an in vitro susceptibility test of anticancer drugs using new types of oxygen electrodes. Bull Educ Res Nihon Univ Sch Dent Matsudo. 2005;7:7–21.
This work was supported in part by a Grant-in-Aid for Scientific Research (B) [No. 20390501 (H.I.)], and a Grant-in-Aid for challenging Exploratory Researches [No. 26670908 and No. 22659314 (H.I.)].
Conflict of interest
The authors declare that they have no conflict of interest.
About this article
Cite this article
Ohyama, A., Toyomura, J., Tachibana, T. et al. Establishment and characterization of a clear cell carcinoma cell line, designated NOCC, derived from human ovary. Human Cell 29, 188–196 (2016). https://doi.org/10.1007/s13577-016-0142-x